Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

SPINEWAY : 1st complex surgery performed in the USA with Spineway's MIS implants


Posted on: 15 Jan 18

Press release                                                                                                                             Ecully, 15 January 2018

1st complex surgery performed in the USA with
Spineway's MIS implants

Spineway, specialist in surgical implants and instruments for treating disorders of the spinal column (spine), announces that the Texas Back Institute (TBI), a group of US hospitals specializing in neck and back pain, performed the first operation addressing scoliosis via minimally invasive surgery using the Group's MONT-BLANC MIS implants.

This complex operation was successfully performed by Dr. Theodore Belanger at the Texas Health Presbyterian Hospital and positions Spineway as an innovative player in the treatment of scoliosis. Indeed, very few laboratories in the world offer solutions adapted to deforming conditions such as scoliosis with a minimally invasive approach.

Prior to this implant, Texas Back Institute performed a series of fifteen surgeries with Spineway's MONT-BLANC MIS implants de Spineway on patients with degenerative conditions.

With 40 years' experience, TBI is currently one of the biggest top-level multidisciplinary university centers in the US. With 9 medical centers and over 20 surgeons throughout the state of Texas, TBI is well-known and has cutting-edge expertise in the treatment of back conditions.

Theodore Belanger, Orthopedic Spine and Scoliosis Surgeon at TBI, said the following about this partnership: "I feel there is great promise in the innovative thinking at the core of Spineway, and I look forward to a strong working relationship between the company and the Texas Back Institute over the coming years!"

Building on this major step forward, Spineway will continue its expansion in the United States and confirms a sharp increase in its revenue for the 2017 financial year.

This press release is available in both English and French. In case of discrepancy, the French version shall prevail.

SPINEWAY IS ELIGIBLE FOR THE PEA-PME

Find out all about Spineway at www.spineway.com

Next communication:
2017 annual revenue - 17 January 2018, after market closes

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.
Spineway has an international network of over 50 independent distributors and 90% of its turnover comes from exports.
Spineway, which is eligible for investment through FCPIs (French unit trusts specializing in innovation), received the OSEO Excellence award as well as the Deloitte Fast 50 award in 2011. Rhône Alpes INPI Patent Innovation Award (2013) - Talent INPI award (2015).
ISIN code: FR0011398874 - Euronext Growth

Contacts:              

   
Investor Relations
David Siegrist - Finance Director
+33 (0)4 72 77 01 52
finance.dsg@spineway.com
  Financial Communication
Jérôme Gacoin / Solène Kennis
+33 (0)1 75 77 54 68
skennis@aelium.fr
Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/8ad5a411-2b11-4b70-882a-c93aa16f26e9

GlobeNewswire
globenewswire.com

Last updated on: 16/01/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.